Brief: Herantis Pharma Announces Positive Interim Data From Lymfactin Study

Herantis Pharma Oyj

16/04/2018 07:07

April 16 (Reuters) - HERANTIS PHARMA OYJ  HRTIS.HE :
    * REG-HERANTIS PHARMA ANNOUNCES POSITIVE INTERIM DATA FROM
LYMFACTIN STUDY IN SECONDARY LYMPHEDEMA
    * PHASE 1 STUDY CONTINUES WITH A 12-MONTH FOLLOW-UP ON
PATIENTS.

Source text for Eikon:  ID:nGNE3xlP1w 
Further company coverage:  HRTIS.HE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))